Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A gynecologic oncology group study

  • Robert A. Burger
  • , Mark F. Brady
  • , Michael A. Bookman
  • , Bradley J. Monk
  • , Joan L. Walker
  • , Howard D. Homesley
  • , Jeffrey Fowler
  • , Benjamin E. Greer
  • , Matthew Boente
  • , Gini F. Fleming
  • , Peter C. Lim
  • , Stephen C. Rubin
  • , Noriyuki Katsumata
  • , Sharon X. Liang

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Fingerprint

Dive into the research topics of 'Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A gynecologic oncology group study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science